

Allison A. Feduccia, Ph.D.

afeduccia.com

Education

Ph.D. in Neuropharmacology, University of Texas, Austin, TX
2009

Bachelor of Science, Louisiana State University, Baton Rouge, LA
Major: Psychology Minor: Biological Sciences
2003

International Study Abroad Program, Biological Psychology, University of
Maastricht, Maastricht, The Netherlands
2001-2002

Experience

Co-Founder and Executive Director. [Project New Day](#), Santa Cruz, CA
2019-present

Co-Founder and CEO. [Psychedelic.Support](#), Santa Cruz, CA
2017-present

Senior Clinical Data Scientist. MAPS Public Benefit Corporation. Santa Cruz, CA
2019-2020

Clinical Data Scientist. MAPS Public Benefit Corporation. Santa Cruz, CA
2017-2019

Clinical Trial Leader. MAPS Public Benefit Corporation. Santa Cruz, CA
2015-2017

Course Developer. Elite Continuing Education University. Austin, TX
2014-2015

Postdoctoral Research Fellow. National Institutes of Health, National Institute on
Alcohol Abuse and Alcoholism, Laboratory of Clinical and Translational Studies,
Bethesda, MD Supervisor: Dr. Lorenzo Leggio
2012-2013

Postdoctoral Researcher. Ernest Gallo Clinic and Research Center, Emeryville,
CA, Preclinical Development. Supervisor: Dr. Selena Bartlett. 2010-2012

Graduate Research Assistant. University of Texas, Austin, TX, Division of
Pharmacology/Toxicology. Supervisor: Dr. Christine Duvauchelle.

2004 - 2009

Teaching Assistant. University of Texas, Austin, TX, Division of Chemistry and Biochemistry. Supervisor: Dr. David Laude 2004

Summer Internship. University of Texas, Austin, TX, Division of Pharmacology/Toxicology. Supervisor: Dr. Andrea C. Gore 2003

Research Assistant. Pennington Biomedical Research Center, Baton Rouge, LA. Supervisor: Dr. Paula Geiselman 2003

Publications

Research Papers

Lourido, I., Bathje, G., Hallsiey, R.R., Booher, J.D., Novick, B., **Feduccia, A. A.** (2021). Practical and Ethical Considerations for Psychedelic Therapy and Integration Practices. *Journal of Psychedelic Psychiatry*, 3(3), 1-19.

Wang, J. B., Lin, J., Bedrosian, L., Coker, A., Jerome, L., **Feduccia, A. A.**, ... & Doblin, R. (2021). Scaling Up: Multisite Open-Label Clinical Trials of MDMA-Assisted Therapy for Severe Posttraumatic Stress Disorder. *Journal of Humanistic Psychology*, 00221678211023663.

Monson, C. M., Wagner, A. C., Mithoefer, A. T., Liebman, R. E., **Feduccia, A. A.**, Jerome, L. I., Yazar-Klosinski, B., Emerson, A., Doblin, R., & Mithoefer, M. C. (2020). MDMA-facilitated cognitive-behavioural conjoint therapy for posttraumatic stress disorder: an uncontrolled trial. *European Journal of Psychotraumatology*, 11(1), 1840123.

Feduccia, A. A., Jerome, L., Mithoefer, M. C., & Holland, J. (2020). Discontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy. *Psychopharmacology*, 1-8.

Wolfson, P. E., Andries, J., **Feduccia, A. A.**, Jerome, L., Wang, J. B., Williams, E., ... & Emerson, A. (2020). MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study. *Scientific reports*, 10(1), 1-15.

Jerome, L., **Feduccia, A. A.**, Wang, J. B., Hamilton, S., Yazar-Klosinski, B., Emerson, A., ... & Doblin, R. (2020). Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials. *Psychopharmacology*.

Gorman, I., Belser, A. B., Jerome, L., Hennigan, C., Shechet, B., Hamilton, S., ... & **Feduccia, A. A.** Posttraumatic Growth After MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder. *Journal of traumatic stress* (2020) 33(2), 161-170.

Mithoefer, M.C., **Feduccia, A.A.**, Jerome, L., Mithoefer, A., Wagner, M., Walsh, Z., Hamilton, S., Yazar-Klosinski, B., Emerson, A. and Doblin, R. MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for Phase 3 trials based on pooled analysis of six Phase 2 randomized controlled trials. *Psychopharmacology* (2019) 1-11.

Ot'alora, G. M., Grigsby, J., Poulter, B., Van Derveer, J. W., Giron, S. G., Jerome, L., **Feduccia, A.A.**, Hamilton, S., Yazar-Klosinski, B., Emerson, A. Doblin, R. (2018). 3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial. *Journal of Psychopharmacology* (2018).

Danforth, A.L., Grob, C.S., Struble, C., **Feduccia, A.A.**, Walker, N., Jerome, L., Yazar-Klosinski, B., Emerson, A. Reduction in Social Anxiety After MDMA-Assisted Psychotherapy with Autistic Adults: A Randomized, Double-blind, Placebo-Controlled Pilot Study. *Psychopharmacology* (2018).

Mithoefer, M.C., Mithoefer, A.T., **Feduccia, A.A.**, Jerome, L., Wagner, M., Wymer, J., Holland, J., Hamilton, S., Yazar-Klosinski, B., Emerson, A. and Doblin, R. 3, 4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. *The Lancet Psychiatry* (2018), 5(6) 486-497.

Neilson, J., **Feduccia, A.A.**, Megler, J., Doblin, R. Therapeutic potential of ayahuasca for posttraumatic stress disorder: results from an anonymous online survey. [Under peer review]

Feduccia, A.A., Simms, J.A., Mill, D.J., Yi, H.Y., Rui, L., Bartlett, S.E. Varenicline decreases ethanol intake and increases dopamine release via neuronal nicotinic acetylcholine receptors in the nucleus accumbens. *British Journal of Pharmacology* 171 (2014) 3420-3431.

Feduccia, A.A., Simms, J.A., Mill, D.J., Yi, H.Y., Quik, M., Bartlett, S.E. Long-term ethanol consumption alters the expression of neural nicotinic acetylcholine receptor subunits and response to varenicline. (in preparation)

Nielsen, CK. Simms, J.A., Rui, L., Mill, D., Yi, H.Y., **Feduccia, A.A.**, Santos, N., Bartlett, S.E. Delta opioid receptor function in the dorsal striatum plays a role in high levels of ethanol consumption in rats. *Journal of Neuroscience* 32 (2012) 4540-4552.

Feduccia, A.A., Wang, Y., Simms, J.A., Yi, H.Y., Rui, L., Bjeldanes, L., Ye, C., Bartlett, S.E. Locomotor activation by theacrine, a purine alkaloid structurally similar to caffeine: Involvement of adenosine and dopamine receptors. *Pharmacology, Biochemistry and Behavior* 102 (2012) 241-248.

Feduccia, A.A., and Duvauchelle, C.L. Novel apparatus and method for drug reward conditioning. *Journal of Visualized Experiments* 42 (2010) pii: 1998.

Feduccia, A.A., and Duvauchelle, C.L. Heat increases MDMA-enhanced NAcc 5-HT and body temperature, but not MDMA self-administration. *European Neuropsychopharmacology* 20 (2010) 884-894.

Feduccia, A.A., and Duvauchelle, C.L. Auditory stimuli enhance MDMA-conditioned reinforcement and MDMA-induced nucleus accumbens dopamine, serotonin and locomotor responses. *Brain Research Bulletin* 77 (2008) 189-196.

Review Articles

Greenway, K.T., Garel, N., Jerome, L., **Feduccia, A.A.** Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments. *Expert Review of Clinical Pharmacology* (2020).

Feduccia, A.A., Mithoefer, M.C. MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms? *Progress in neuro-psychopharmacology and biological psychiatry* 84 (2018) 221-228.

Feduccia, A.A., Holland, J., Mithoefer, M.C. Progress and promise for the MDMA drug development program. *Psychopharmacology* (2017) 1-11.

Feduccia, A.A., Chatterjee, S., Bartlett, S.E. Neuronal nicotinic acetylcholine receptor: neuroplastic changes underlying alcohol and nicotine addictions. *Frontiers in Molecular Neuroscience* 5:83 (2012) 1-18.

Book Chapters

Feduccia, A.A., Leggio, L. Chapter 8: Clinical research on the ghrelin axis and alcohol consumption. *Central Functions of the Ghrelin Receptor* 25 (2014).

Letters to Editors

Ali, I.L., **Feduccia, A.A.**, Jerome, I.J., Ginsberg, N.L. MAPS Responds to Administration's Letter about Psychedelic Research Agenda and Findings. Letter to FDA and NIH (2019).

<https://maps.org/news/media/7801-statement-maps-responds-to-administration%E2%80%99s-letter-about-psychedelic-research-agenda-and-findings>

Feduccia, A.A., Mithoefer, M.C., Jerome, L., Holland, J., Emerson, A., Doblin, R. Response to the Consensus Statement of the PTSD Psychopharmacology Working Group. *Biological Psychiatry* (2017).

Jerome, L., **Feduccia, A.A.**, Mithoefer, M.C., Doblin, R. Defending MDMA as a Treatment for PTSD. Medscape (2017). <https://www.medscape.com/viewarticle/889639>

Articles for Lay Audiences

Feduccia, A.A. FDA and NIH Perspectives on Psychedelic Drug Development. Psychedelic Support, June 2019. <https://psychedelic.support/resources/fda-nih-perspectives-psychedelic-drug-development/>

Feduccia, A.A. MDMA Breakthrough Therapy Designation Results Published. Psychedelic Support, May 2019. <https://psychedelic.support/resources/mdma-breakthrough-therapy-designation-results-published/>

Feduccia, A.A. and Ortigo, K. How to Become a Psychedelic Therapist. Psychedelic Support, March 2019. <https://psychedelic.support/resources/training-psychedelic-therapist/>

Feduccia, A.A. Can We Quantify the Placebo Effect in Psychedelic Medicine? Psychedelic Support, March 2019. <https://psychedelic.support/resources/placebo-effect-psychedelics-medicine/>

Feduccia, A.A. Healing trauma with MDMA: a new study published. Psychedelic Support, October 2018. <https://psychedelic.support/resources/healing-trauma-with-mdma-a-new-study-published/>

Feduccia, A.A. New Use for Psychedelics. Proto Magazine. Second Opinion, September 2018. <http://protomag.com/articles/second-opinion-fall-2018>

Feduccia, A.A. First clinical trial: social anxiety in autistic adults successfully treated with MDMA therapy. Psychedelic Support, September 2018. <https://psychedelic.support/resources/first-clinical-trial-autism-mdma-2/>

Feduccia, A.A. Psychedelic Support: innovation through use of technology. Chacruna, September 2018. <https://chacruna.net/psychedelic-support-innovation-technology/>

Feduccia, A.A. How to join a psychedelic clinical trial. Psychedelic Support, July 2018. <https://psychedelic.support/resources/how-to-join-psychedelic-clinical-trial/>

Feduccia, A.A. Do psychedelics have the power to change minds? Chacruna, July 2018. <http://chacruna.net/do-psychedelics-have-the-power-to-change-minds/>

Feduccia, A.A. How psychedelics help neurons grow. Psychedelic Support, June 2018.
<https://psychedelic.support/resources/how-psychedelics-help-neurons-grow/>

Jerome, L., **Feduccia, A.A.** From Print to Presentations: The Importance of Communicating Findings from Psychedelic and Cannabis Studies. MAPS Bulletin Spring 2018 (28), No. 1.
<https://maps.org/news/bulletin/articles/429-maps-bulletin-spring-2018-vol-28-no-1/7259-from-print-to-presentations-spring-2018>

Emerson, A., Yazar-Klosinski, B., **Feduccia, A.A.**, Jerome, L., Doblin, R. Treating PTSD with MDMA-Assisted Psychotherapy: Product Development Status and Proposed Design for Phase 3 Clinical Trials. MAPS Bulletin Winter 2016 (26), No. 3.
<https://maps.org/news/bulletin/articles/410-bulletin-winter-2016/6400-mdma-ptsd-2016>

Invited Scholarly Presentations and Symposia

Kaiser Permanente Mental Health Training Program. “New Frontiers in Psychedelics and Mental Health” Virtual, January 2022.

Double Blind Seminar Series. “Psychedelics for Menstruation, Pregnancy, Menopause, & More” Virtual, December 19, 2021.

Chacruna Institute. “Ethics, Safety, and Abuse in Psychedelic Medicine” Virtual, December 8, 2021.

FDA and Duke Margolis Center for Health Policy (private workshop), Development and Regulation of Psychedelics for Therapeutic Use. “Use of MDMA Treatment of PTSD” Virtual, April 2021.

Invited scholarly presentation. Stanford University, Introduction to Psychedelic Medicine. “MDMA-assisted Psychotherapy for the Treatment of Anxiety Related Conditions” Stanford, CA, January 23, 2020.

MAPS Psychedelic Science Summit. “MDMA-Assisted Psychotherapy: Exploring the Role of Receptors, Neurons, and Brain Circuits” Austin, TX, October 2019.

International Society for Research on Psychedelics 1st Annual Meeting. “An Open-label, Multi-site Phase 2 MDMA-assisted Psychotherapy Trial for Severe PTSD and Supervision of New Co-therapy Teams” New Orleans, LA, October 2019.

Trailblazers Meeting

American Society for Clinical Psychopharmacology Annual Meeting. “An Open-Label, Multi-Site Phase 2 MDMA-Assisted Psychotherapy Trial for Severe Posttraumatic Stress Disorder and Supervision of New Co-Therapy Teams.” Scottsdale, AZ, May 2019.

Pharmaceutical Pipeline Presentation. “MDMA-Assisted Psychotherapy for Treatment of Anxiety Related to Life-Threatening Illnesses.” American Society for Clinical Psychopharmacology Annual Meeting. Scottsdale, AZ, May 2019.

Invited scholarly presentation. “A Breakthrough for Psychiatric Medicine MDMA-assisted Psychotherapy.” Palo Alto University, Association for Traumatic Stress Speaker Series. Palo Alto, CA, May 2019.

Invited scholarly presentation. “A Breakthrough for Psychiatric Medicine MDMA-assisted Psychotherapy.” Academy of Sciences. San Francisco, CA, April 2019.

Invited scholarly presentation. “Drugs, Set, and Setting.” National Center for PTSD. Palo Alto, CA, December 2018.

Cultural and Political Perspectives on Psychedelic Science at the California Institute for Integral Studies. “Psychedelic Support: Utilizing Technology to Build a New Healthcare Platform.” San Francisco, CA, August 2018.

Drug Development Pipeline Presentation. “MDMA-assisted Psychotherapy for Treatment of Chronic PTSD: Finding from MAPS-sponsored Phase 2 Clinical Research Trials.” American Society for Clinical Psychopharmacology. Miami, FL, May 2018.

Invited scholarly presentation. “MDMA Therapy: Will it Change the Face of Psychiatric Medicine?” Sutter Hospital Ground Rounds. CA, April 2018.

The 51st Annual Winter Conference on Brain Research. “MDMA-assisted Psychotherapy for Treatment of Chronic PTSD.” Whistler, British Columbia, Canada, January 2018.

Bass Coast Festival. “Cannabis and Psychedelics: Ancient Technologies/Modern Medicines.” Merritt BC, Canada, July 2017.

Invited scholarly presentation. “MDMA Therapy: Will it Change the Face of Psychiatric Medicine?” San Mateo Hospital Ground Rounds. San Mateo, CA, June 2017.

Invited scholarly presentation. “MDMA Therapy: Will it Change the Face of Psychiatric Medicine?” Palo Alto University. Palo Alto, CA, May 2017.

The 7th Annual Canadian Military and Veteran Health Research Forum (CIMVHR), symposium on Mental Health: Deployment and PTSD. “MDMA-assisted Psychotherapy for Treatment of Chronic PTSD: Findings from MAPS-Sponsored Phase 2 Clinical Research Trials.” Vancouver BC, Canada, November 2016. Winner of the Homewood Mental Health Treatment Award: "An award sponsored by Homewood Health Centre for the best presentation focusing on improving and innovating clinical mental health practice at Forum 2016." (\$500 prize)

PTSD Causes, Consequences, Responses Multidisciplinary Conference, Panel for New Approaches in PTSD Therapy: “MDMA-assisted Psychotherapy for Treatment of Chronic PTSD: Findings from MAPS-Sponsored Phase 2 Clinical Research Trials.” St. John’s, Newfoundland and Labrador, Canada, July 2016.

The 2013 State of the Art Course in Addiction Medicine by the American Society of Addiction Medicine, Session on alcohol pharmacotherapy: Translation and barriers to use. “Neuronal nicotinic acetylcholine receptors in the development and treatment of alcohol use disorders.” Arlington, VA, October 2013.

The Laboratory of Clinical and Translational Studies at the National Institute on Alcohol Abuse and Alcoholism, Symposium on translational development of varenicline for alcohol use disorders, “Nicotinic acetylcholine receptors in the development and treatment of alcohol use disorders.” Bethesda, MD, September 2013.

The 35th Annual Meeting of the Research Society on Alcoholism, Symposium on medication development for alcohol dependence, nicotine dependence, and their co-occurrence: translational approaches, “Nicotinic acetylcholine receptors in the development and treatment of alcohol use disorders.” San Francisco, CA, June 2012.

Media Interviews

Interview with Forbes. Santa Cruz is Third U.S. City to Decriminalize Psilocybin, Plant Medicine, As Advocacy Expands.

<https://www.forbes.com/sites/davidcarpenter/2020/02/01/santa-cruz-is-third-us-city-to-decriminalize-psilocybin-plant-medicine-as-advocacy-expands/#1d6397565d0d>

Interview with WebMD. Can Psychedelic Ayahuasca Help with Depression?

<https://www.webmd.com/depression/news/20191031/can-psychedelic-ayahuasca-help-with-depression>

Interview with PsyPost. Results from phase 2 trials indicate MDMA-assisted psychotherapy for PTSD is safe and effective. May 2019. <https://www.psypost.org/2019/05/results-from-phase-2-clinical-trials-indicate-mdma-assisted-psychotherapy-is-safe-and-effective-53681>

Interview with Psymposia. Psychedelic support creates a network for psychedelic therapists. November 2018. <https://www.psymposia.com/magazine/psychedelic-support-creates-a-network-for-psychedelic-therapists/>

Interview with The Washington Post. This is what happens to a shy octopus on ecstasy. September 2018. https://www.washingtonpost.com/science/2018/09/20/this-is-what-happens-shy-octopus-ecstasy/?utm_term=.210e8da3504f

Interview with Smithsonian Magazine. Ecstasy turns antisocial octopuses into lovestruck cuddle buddies – just like us. September 2018. <https://www.smithsonianmag.com/science-nature/ecstasy-turns-antisocial-octopuses-lovestruck-cuddle-buddies-just-us-180970363/>

Interview with Medscape. MDMA-assisted psychotherapy mitigates PTSD symptoms. June 2018. https://www.medscape.com/viewarticle/897652?src=soc_tw_180605_mscedpt_news_psych_mdma&faf=1

Interview with The Guardian. Ecstasy ingredient could help ease PTSD symptoms, study finds. May 2018. <https://www.theguardian.com/science/2018/may/01/ecstasy-ingredient-could-help-ease-ptsd-symptoms-study-finds>

Interview with WebMD. Ecstasy may help some with PTSD, but risks remain. May 2018. <https://www.webmd.com/mental-health/news/20180501/ecstasy-may-help-some-with-ptsd-but-risks-remain-1>

Interview with WikiTribune. Q&A: Could MDMA trials lead to a breakthrough in the treatment of PTSD? May 2018. <https://www.wikitribune.com/article/73842/>

Interview with Reuters. Ecstasy therapy may help service veterans suffering PTSD. May 2018. <https://www.reuters.com/article/us-health-mdma/ecstasy-therapy-may-help-service-veterans-suffering-ptsd-idUSKBN1I24IK>

Video interview with ABC10. Are psychedelics the new medical marijuana? May 2017. <https://www.abc10.com/article/news/are-psychedelics-the-new-medical-marijuana/437183747>

Interview with The Guardian. A puke bucket and ancient drug: is ayahuasca the future of PTSD treatment? April 2017. <https://www.theguardian.com/science/blog/2017/apr/06/a-puke-bucket-and-an-ancient-drug-is-ayahuasca-the-future-of-ptsd-treatment->

Radio interview with CBC Radio-Canada. Can MDMA help combat PTSD? November 2016. <https://www.cbc.ca/news/canada/british-columbia/can-mdma-help-combat-post-traumatic-stress-disorder-1.3868713>

Podcasts

The Psychedelic Entrepreneur Podcast. Ethics, Community & Responsibility through Psychedelic Support. November 16, 2021. <https://open.spotify.com/episode/5wMHweQ1UAWgqrdRDRWBz0>

Soul Seekr Podcast. Psychedelic Support & Project New Day. November, 2021. <https://podcasts.apple.com/au/podcast/107-psychedelic-support-project-new-day-w-alli-feduccia/id1474728691?i=1000538312398>

Plant Media Project Podcast. The Vine Featuring Allison Feduccia. March 29, 2021. <https://plantmediaproject.com/post/the-vine-featuring-allison-feduccia>

Abstracts and Proceedings in National and International Meetings

Feduccia, A.A., Jerome, L., Yazar-Klosinski, B., Emerson, A., Mithoefer, M. “An Open-Label, Multi-Site Phase 2 MDMA-Assisted Psychotherapy Trial for Severe Posttraumatic Stress Disorder and Supervision of New Co-Therapy Teams.” American Society for Clinical Psychopharmacology Annual Meeting. Scottsdale, AZ, May 2019.

Feduccia, A.A., Jerome, L., Yazar-Klosinski, B., Mithoefer, M. “MDMA-assisted Psychotherapy for Treatment of Anxiety Related to Life-threatening Illnesses.” American Psychiatric Association Annual Meeting. San Francisco, CA, May 2019.

Jerome, L., **Feduccia, A.A.**, Mithoefer, M. “MDMA-assisted Psychotherapy Reduces PTSD Symptoms: Pooled Analysis across Randomized, Controlled Blinded Trials.” American Psychiatric Association Annual Meeting. San Francisco, CA, May 2019.

Mithoefer M, Mithoefer A, **Feduccia A.A.**, Jerome I, Wagner M, Hoiland J, Hamilton S, Yazar-Klosinski B, Emerson A, Doblin R. “MDMA-assisted psychotherapy for PTSD: A promising novel experimental treatment moving into phase 3 trials with FDA breakthrough therapy designation.” European Neuropsychopharmacology. 2019 Jan 1;29:S11-2.

Feduccia, A.A., Yazar-Klosinski, B, Jerome, L., Mithoefer, M., Emerson, A., Doblin, R. “MDMA-assisted Psychotherapy for Treatment of Chronic PTSD: Finding from MAPS-sponsored Phase 2 Clinical Research Trials.” American Society for Clinical Psychopharmacology Annual Meeting. Miami, FL, May 2018.

C. Reiff, B. Poulter, **A. A. Feduccia**, J. Grigsby, J. Van Derveer, L. Jerome, B. Yazar-Klosinski, A. Emerson, R. Doblin, M. Mithoefer, M. Ot’alora G. MDMA-assisted Psychotherapy for Treatment of PTSD: A Profound Change. The American Public Health Association (APHA) Annual Meeting and Expo. Atlanta, GA, June 2017.

A.A. Feduccia, M.Mithoefer, A. Mithoefer, M. Wagner, J. Wymer, J. Hollan³. MDMA-assisted Psychotherapy for Treatment of PTSD in Military Veterans, Firefighters, and Police Officers and

Results from Phase 2 Clinical Trials. Military Health Research Symposium. Orlando, FL, August 2017.

Feduccia, A.A., Yazar-Klosinski, B, Jerome, L., Mithoefer, M., Emerson, A., Doblin, R. MDMA-assisted Psychotherapy for Treatment of Chronic PTSD: Findings from MAPS-Sponsored Phase 2 Clinical Research Trials. Poster presented at Posttraumatic Stress Disorder (PTSD) State of the Science Summit (SoSS) entitled “Pathophysiology of PTSD: Rethinking Drug Targets,” Shepherdstown, WV, June 2017.

Feduccia, A.A., Yazar-Klosinski, B, Jerome, L., Mithoefer, M., Emerson, A., Doblin, R. MDMA-assisted Psychotherapy for Treatment of Chronic PTSD: Findings from MAPS-Sponsored Phase 2 Clinical Research Trials. Poster presented at Psychedelic Science Conference, Oakland, CA, April 2017.

Feduccia, A.A., Yazar-Klosinski, B, Jerome, L., Mithoefer, M., Emerson, A., Doblin, R. MDMA-assisted Psychotherapy for Treatment of Chronic PTSD: Findings from MAPS-Sponsored Phase 2 Clinical Research Trials. Poster presented at The 46th Annual Meeting of the Society for Neuroscience, San Diego, CA, November 2016.

Feduccia A.A., Suchankova P, Schwandt ML, Lee MR, Oot E, Bollinger JW, Lexi AA, Goldman D, Hodgkinson C, George DT, Hommer DW, Heilig M, Ramchandani VA, Leggio L. Genetic variations in the preproghrelin in gene (GHRL) are associated with alcohol drinking behaviors. Poster presented at The Translational Science Conference, Washington, D.C., April 2013.

Lee, M.R., Schwandt, M., **Feduccia, A.A.**, Bollinger, J., Dias, L.A., Oot, E., George, D.T., Hommer, D.W., Goldman, D., Hodgkinson, C., Heilig, M., Leggio, L. Effect of functionally significant deiodinase SNP's on thyroid hormone levels, dependence severity and craving in alcohol dependence. Poster presented at *The 36th Annual Meeting of the Research Society on Alcoholism*; Orlando, FL, June 2013.

Bollinger, J., Lee, M., Suchankova, P., Schwandt, M., **Feduccia, A.A.**, Dias, L.A., Oot, E.N., George, D., Goldman, D., Hodgkinson, C., Heilig, M., & Leggio, L. Possible role of thyroid stimulating hormone (TSH) on alcohol consumption in alcoholic and non-alcoholic individuals. Poster presented at the *Postbaccalaureate Poster Day*; Bethesda, MD, May 2013.

Dias, L.A., Oot, E.N., Bollinger, J., Coe, M., Schwandt, M., Suchankova, P., **Feduccia, A.A.**, Lee, M., Ramchandani, V.A., Leggio, L. Feeding-related hormones and intravenous alcohol administration in social drinkers. Poster presented at the *Postbaccalaureate Poster Day*; Bethesda, MD, May 2013.

Oot, E.N., Dias, L.A., Bollinger, J., Coe, M., Schwandt, M., **Feduccia, A.A.**, Suchankova, P., Lee, M., Ramchandani, V.A., Leggio, L. Does intravenous alcohol administration affect plasma ghrelin levels? A pilot study on social drinkers. Poster presented at the *Postbaccalaureate Poster Day*; Bethesda, MD, May 2013.

Feduccia, A.A., Suchankova, P., Schwandt, M.L., Yan, J., Lee, M.R., Oot, E.N., Bollinger, J.W., Dias, A.A., Goldman, D., Hodgkinson, C., George, D.T., Hommer, D.W., Heilig, M., Ramchandani, V.A., Leggio, L. Polymorphisms in the preproghrelin gene (GHRL) are associated with alcohol drinking behaviors. The 36th Annual Meeting of the Research Society on Alcoholism, Orlando, FL June 2013.

Feduccia, A.A., Simms, J.A., Mill, D.J., Yi, H.Y., Chatterjee, S., Bartlett, S.E. Varenicline regulates ethanol consumption in rats by actions in the nucleus accumbens. The 35th Annual Meeting of the Research Society on Alcoholism, San Francisco, CA, June 2012.

Feduccia, A.A., Simms, J.A., Mill, D.J., Yi, H.Y., Chatterjee, S., Bartlett, S.E. Varenicline regulates ethanol consumption in rats by actions in the mesolimbic dopaminergic system. The 41th Annual Meeting of the Society for Neuroscience, Washington D.C., November 2011.

Feduccia, A.A., Chatterjee, S., Steensland, P., Simms, J.A., Holgate, J., Bito-Onon, J.J., Bartlett, S.E. Varenicline, an inhibitor of neuronal nicotinic acetylcholine receptors, is more efficacious in high and long-term ethanol consuming rats. The 34th Annual Meeting of the Research Society on Alcoholism, Atlanta, GA, June 2011.

Feduccia, A.A., Chatterjee, S., Steensland, P., Simms, J.A., Holgate, J., Coe, J.W., Hurst, C.L., Lowe, J., Rollema, H., Bartlett, S.E. The $\alpha 3\beta 4^*$ neuronal nicotinic acetylcholine receptor plays an important role in ethanol consumption and seeking. The 40th Annual Meeting of the Society for Neuroscience, San Diego, CA, November 2010.

Feduccia, A.A., McAleer, L.M., Duvauchelle, C.L. Novel apparatus and method for drug reward conditioning. The 39th Annual Meeting of the Society for Neuroscience, Chicago, IL, October 2009.

Feduccia, A.A. and Duvauchelle, C.L. Ecstasy: Hot environments and electronic music enhances self-administration and serotonin response in rats. The 38th Annual Meeting of the Society for Neuroscience, Washington D.C., November 2008.

Garza, T., **Feduccia, A.A.**, Duvauchelle, C.L. The behavioral and neurochemical parameters associated with 3,4-methylenedioxymethamphetamine (MDMA) self-administration and thermal stimuli. University of Texas College of Pharmacy Celebrating Research Achievements, Austin, TX, April 2008.

Reveron, M.E., **Feduccia, A.A.**, Duvauchelle, C.L. MDMA self-administration under a progressive ratio schedule in rats. The 37th Annual Meeting of the Society for Neuroscience, San Diego, CA, November 2007.

Michel, E., **Feduccia, A.A.**, Duvauchelle, C.L. Behavioral and neurochemical changes associated with 3,4-methylenedioxymethamphetamine (MDMA) self-administration and auditory stimuli. University of Texas College of Pharmacy Celebrating Research Achievements, Austin, TX, April 2007.

Feduccia, A.A., and Duvauchelle, C.L. Effects of auditory stimuli on 3,4-methylenedioxymethamphetamine induced conditioned place preference and extracellular DA and 5-HT in rats. The Pavlovian Society Annual Meeting, Austin, TX, October, 2007.

Feduccia, A.A., and Duvauchelle, C.L. Effect of various auditory stimuli on 3,4-methylenedioxymethamphetamine (MDMA) conditioned place preference and self-administration in rats. The 36th Annual Meeting of the Society for Neuroscience, Atlanta, GA, October 2006.

Gore, A.C., **Feduccia, A.A.**, Choudhury, L., Yin, W., Steinberg, R.M., Maffucci, J.A., and Hughes S. Blockade of the nocturnal increase in GnRH release delays the onset of puberty in female rats. The 86th Annual Meeting of the Endocrine Society, New Orleans, LA, June 2004.